目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 IMPACT OF AI/GENERATIVE AI

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 MARKET SIZE ESTIMATION
2.2.2 TOP-DOWN APPROACH
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 GENOMICS MARKET OVERVIEW
4.2 ASIA PACIFIC: GENOMICS MARKET, BY OFFERING
4.3 GENOMICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 GENOMICS MARKET SHARE, BY PRODUCT END USER, 2023

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing government funding for genomics projects
5.2.1.2 Increasing prevalence of viral and inherited disorders
5.2.1.3 Advancements in NGS platforms
5.2.1.4 Growing applications of genomics
5.2.2 RESTRAINTS
5.2.2.1 High investment costs
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing use of genomics in precision medicine
5.2.3.2 Technological advancements in genomics
5.2.4 CHALLENGES
5.2.4.1 Handling of large volumes of data sets and their analysis
5.2.4.2 Clinical utility of genomics
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.4 REGULATORY LANDSCAPE
5.4.1 REGULATORY SCENARIO
5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.5 VALUE CHAIN ANALYSIS
5.6 TECHNOLOGICAL ANALYSIS
5.6.1 KEY TECHNOLOGIES
5.6.1.1 Sequencing by synthesis
5.6.1.2 Single-molecule real-time sequencing
5.6.1.3 Nanopore sequencing
5.6.1.4 qPCR
5.6.1.5 dPCR
5.6.1.6 Microarray technology
5.6.2 COMPLEMENTARY TECHNOLOGIES
5.6.2.1 Cytogenetics
5.6.2.2 Synthetic biology
5.6.2.3 Multiomics
5.6.2.4 Single-cell analysis
5.6.3 ADJACENT TECHNOLOGIES
5.6.3.1 Sample preparation technologies
5.6.3.2 Data analysis
5.6.3.3 Bioinformatics and computational biology
5.6.3.4 Artificial intelligence and machine learning
5.7 PRICING ANALYSIS
5.7.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY OFFERING
5.7.1.1 Average selling price of key players, by instrument
5.7.1.2 Average selling price of key players, by consumable
5.7.1.3 Average selling price of key players, by service
5.7.2 AVERAGE SELLING PRICE, BY REGION
5.8 PATENT ANALYSIS
5.9 SUPPLY CHAIN ANALYSIS
5.10 ECOSYSTEM ANALYSIS
5.11 KEY CONFERENCES AND EVENTS, 2024-2025
5.12 PORTER'S FIVE FORCES ANALYSIS
5.12.1 PORTER'S FIVE FORCES ANALYSIS
5.12.2 INTENSITY OF COMPETITIVE RIVALRY
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 THREAT OF SUBSTITUTES
5.12.6 THREAT OF NEW ENTRANTS
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 KEY BUYING CRITERIA, BY END USER
5.14 INVESTMENT AND FUNDING SCENARIO
5.15 CASE STUDY ANALYSIS
5.16 TRADE ANALYSIS
5.16.1 IMPORT VALUE FOR FLOW CYTOMETERS (HS CODE 902780), 2017-2021
5.16.2 EXPORT VALUE FOR FLOW CYTOMETERS (HS CODE 902780), 2017-2021
5.16.3 IMPORT DATA FOR FLOW CYTOMETERS (HS CODE 902780), 2022-2023
5.16.4 EXPORT DATA FOR FLOW CYTOMETERS (HS CODE 902780), 2022-2023
5.17 IMPACT OF AI ON GENOMICS MARKET

6 GENOMICS MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCTS
6.3 SERVICES

7 GENOMICS MARKET, BY PRODUCT TYPE
7.1 INTRODUCTION
7.2 REAGENTS, KITS, AND CONSUMABLES
7.2.1 LARGE NUMBER OF PLAYERS OPERATING IN CONSUMABLES SPACE PROPEL DEMAND FOR CONSUMABLES, KITS, AND REAGENTS
7.3 INSTRUMENTS
7.3.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH
7.4 BIOINFORMATICS TOOLS
7.4.1 BIOINFORMATICS TOOLS TO HELP TURN RAW DATA INTO MEANINGFUL INSIGHTS

8 GENOMICS PRODUCTS MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
8.2 SEQUENCING
8.2.1 DIRECT DETECTION OF DNA MODIFICATIONS DURING SEQUENCING TO DRIVE MARKET GROWTH
8.3 PCR
8.3.1 RISING DEMAND FOR BIOMARKER DISCOVERY TO PROPEL MARKET GROWTH
8.4 GENE EDITING
8.4.1 RISING DEMAND FOR NEWER THERAPEUTIC APPROACH DRIVING GROWTH
8.5 FLOW CYTOMETRY
8.5.1 RISING DEMAND FOR FLOW CYTOMETRY FOR AGRIGENOMICS TO DRIVE MARKET GROWTH
8.6 MICROARRAYS
8.6.1 RISING ADOPTION OF HIGH THROUGHPUT TECHNOLOGIES LIMITING MARKET GROWTH
8.7 IN SITU HYBRIDIZATION
8.7.1 INCREASING DEMAND FOR PRECISE GENE EXPRESSION ANALYSIS DRIVING GROWTH OF SEGMENT
8.8 OTHER TECHNOLOGIES

9 GENOMICS PRODUCTS MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS, DIAGNOSTIC LABORATORIES, AND CLINICS
9.2.1 INCREASED APPLICATION IN DISEASE DIAGNOSTICS AND TREATMENT DRIVING MARKET GROWTH
9.3 ACADEMIC AND RESEARCH INSTITUTES
9.3.1 RISING RESEARCH INTENSITY FOR GENOMICS RESEARCH AMONG INSTITUTES TO SUPPORT MARKET GROWTH
9.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
9.4.1 RISING DEMAND FOR COMPREHENSIVE GENOMIC DATA IN CLINICAL GENOMICS IS DRIVING GROWTH
9.5 CROS
9.5.1 RISING COLLABORATION BETWEEN PHARMA COMPANIES AND CROS DRIVING MARKET GROWTH
9.6 OTHER END USERS

10 GENOMICS MARKET, BY SERVICE TYPE
10.1 INTRODUCTION
10.2 GENOMIC PROFILING AND SEQUENCING SERVICES
10.2.1 INCREASED ADOPTION OF SEQUENCING TECHNOLOGIES IN CLINICAL ADOPTION TO SUPPORT MARKET GROWTH
10.3 SAMPLE PREPARATION AND LIBRARY PREPARATION SERVICES
10.3.1 INCREASED DEMAND FOR ONCOLOGY AND RARE DISEASE DIAGNOSTICS TO DRIVE MARKET GROWTH
10.4 BIOINFORMATICS SERVICES
10.4.1 RISING DEMAND FOR ADVANCED PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH

11 GENOMICS MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 DRUG DISCOVERY AND DEVELOPMENT
11.2.1 DRUG DISCOVERY AND DEVELOPMENT TO BE LARGEST APPLICATION IN GENOMICS MARKET
11.3 DIAGNOSTICS
11.3.1 RISING DEMAND DUE TO CLINICAL GENOMICS TO SUPPORT MARKET GROWTH
11.3.1.1 Oncology
11.3.1.1.1 Rising demand for targeted therapies to drive market growth
11.3.2 INFECTIOUS DISEASES
11.3.2.1 Rising demand for comprehensive genomic data in clinical genomics to drive market growth
11.3.3 REPRODUCTIVE HEALTH
11.3.3.1 Rising focus on genetic diseases to drive market growth
11.3.4 OTHER DIAGNOSTIC APPLICATIONS
11.3.4.1 Rising demand for comprehensive genomic data in clinical genomics to drive market growth
11.3.5 AGRICULTURE AND ANIMAL RESEARCH
11.3.5.1 Genomics to help improve crop productivity
11.4 OTHER APPLICATIONS

12 GENOMICS MARKET, BY STUDY TYPE
12.1 INTRODUCTION
12.2 FUNCTIONAL GENOMICS
12.2.1 INCREASED FOCUS ON FUNCTIONAL GENOME STUDIES TO DRIVE MARKET GROWTH
12.3 BIOMARKER DISCOVERY
12.3.1 RISING DEMAND FOR PRECISION MEDICINE TO SUPPORT MARKET GROWTH
12.4 PATHWAY ANALYSIS
12.4.1 RISING PREVALENCE OF COMPLEX DISEASES TO AUGMENT MARKET GROWTH
12.5 EPIGENOMICS
12.5.1 RISING INVESTMENTS FOR EPIGENETICS RESEARCH TO BOOST MARKET GROWTH
12.6 OTHER STUDY TYPES

13 GENOMICS SERVICES MARKET, BY END USER
13.1 INTRODUCTION
13.2 HOSPITALS, DIAGNOSTIC LABORATORIES, AND CLINICS
13.2.1 INCREASED APPLICATION IN DISEASE DIAGNOSTICS AND TREATMENT DRIVING MARKET GROWTH
13.3 ACADEMIC AND RESEARCH INSTITUTES
13.3.1 RISING RESEARCH INTENSITY FOR GENOMICS RESEARCH AMONG INSTITUTES TO SUPPORT MARKET GROWTH
13.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
13.4.1 RISING DEMAND FOR COMPREHENSIVE GENOMIC DATA IN CLINICAL GENOMICS TO DRIVE GROWTH
13.5 OTHER END USERS

14 GENOMICS MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
14.2.2 US
14.2.2.1 US expected to dominate market in North America
14.2.3 CANADA
14.2.3.1 Increasing government initiatives in genomics research to boost market growth
14.3 EUROPE
14.3.1 EUROPE: MACROECONOMIC OUTLOOK
14.3.2 GERMANY
14.3.2.1 Germany to dominate European genomics market
14.3.3 UK
14.3.3.1 Strategic initiatives and funding for genomics research to support market growth
14.3.4 FRANCE
14.3.4.1 Increasing government investment in genomics research to drive growth
14.3.5 ITALY
14.3.5.1 Favorable funding scenario to drive adoption of advanced sequencing technology
14.3.6 SPAIN
14.3.6.1 Growing focus on advancements in personalized medicine to support market growth
14.3.7 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
14.4.2 CHINA
14.4.2.1 China to dominate Asia Pacific market during forecast period
14.4.3 JAPAN
14.4.3.1 Rising number of collaborations in genomics to drive market
14.4.4 INDIA
14.4.4.1 Government and private initiatives for genomics to propel market
14.4.5 AUSTRALIA
14.4.5.1 Increased genomics research in Australia to support market growth
14.4.6 SOUTH KOREA
14.4.6.1 Demand for advanced sequencing technologies to support market growth in South Korea
14.4.7 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
14.5.2 BRAZIL
14.5.2.1 Increased government investments in genomics advancements to drive market in Brazil
14.5.3 MEXICO
14.5.3.1 Rising demand for chronic disease treatment to support market growth in Mexico
14.5.4 REST OF LATIN AMERICA
14.6 MIDDLE EAST
14.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
14.6.2 GCC COUNTRIES
14.6.2.1 Saudi Arabia
14.6.2.1.1 Growing healthcare expenditure in Saudi Arabia to boost market growth
14.6.2.2 United Arab Emirates
14.6.2.2.1 Growing collaborations to advance genome sequencing to aid market growth in UAE
14.6.2.3 Rest of GCC Countries
14.6.3 REST OF MIDDLE EAST
14.7 AFRICA
14.7.1 GROWING FOCUS ON PRECISION MEDICINE TO PROPEL MARKET IN AFRICA
14.7.2 AFRICA: MACROECONOMIC OUTLOOK

15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
15.3 REVENUE ANALYSIS
15.4 MARKET SHARE ANALYSIS
15.5 BRAND/PRODUCT COMPARATIVE ANALYSIS
15.5.1 ILLUMINA, INC.
15.5.2 THERMO FISHER SCIENTIFIC INC.
15.5.3 DANAHER CORPORATION
15.5.4 ROCHE
15.5.5 QIAGEN
15.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
15.6.1 STARS
15.6.2 EMERGING LEADERS
15.6.3 PERVASIVE PLAYERS
15.6.4 PARTICIPANTS
15.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
15.7.1 PROGRESSIVE COMPANIES
15.7.2 RESPONSIVE COMPANIES
15.7.3 DYNAMIC COMPANIES
15.7.4 STARTING BLOCKS
15.7.5 COMPETITIVE BENCHMARKING
15.8 VALUATION AND FINANCIAL METRICS OF GENOMICS VENDORS
15.9 COMPETITIVE SCENARIO
15.9.1 DEALS
15.9.2 EXPANSIONS

16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 ILLUMINA, INC.
16.1.1.1 Business overview
16.1.1.2 Products/Services offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches
16.1.1.3.2 Deals
16.1.1.3.3 Expansions
16.1.1.4 MnM view
16.1.1.4.1 Key strengths
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses and competitive threats
16.1.2 THERMO FISHER SCIENTIFIC INC.
16.1.2.1 Business overview
16.1.2.2 Products/Services offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches
16.1.2.3.2 Deals
16.1.2.3.3 Expansions
16.1.2.4 MnM view
16.1.2.4.1 Key strengths
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses and competitive threats
16.1.3 F. HOFFMANN-LA ROCHE LTD.
16.1.3.1 Business overview
16.1.3.2 Products/Services offered
16.1.3.2.1 Product launches
16.1.3.2.2 Deals
16.1.3.3 MnM view
16.1.3.3.1 Key strengths
16.1.3.3.2 Strategic choices
16.1.3.3.3 Weaknesses and competitive threats
16.1.4 DANAHER CORPORATION
16.1.4.1 Business overview
16.1.4.2 Products/Services offered
16.1.4.2.1 Product launches
16.1.4.2.2 Deals
16.1.4.2.3 Expansions
16.1.5 QIAGEN
16.1.5.1 Business overview
16.1.5.2 Products/Services offered
16.1.5.3 Recent developments
16.1.5.3.1 Deals
16.1.5.3.2 Expansions
16.1.6 AGILENT TECHNOLOGIES, INC.
16.1.6.1 Business overview
16.1.6.2 Products/Services offered
16.1.6.3 Recent developments
16.1.6.3.1 Deals
16.1.6.3.2 Expansions
16.1.7 REVVITY
16.1.7.1 Business overview
16.1.7.2 Products/Services offered
16.1.7.3 Recent developments
16.1.7.3.1 Product launches
16.1.7.3.2 Deals
16.1.7.3.3 Expansions
16.1.8 LABORATORY CORPORATION OF AMERICA HOLDINGS
16.1.8.1 Business overview
16.1.8.2 Services offered
16.1.8.3 Recent developments
16.1.8.3.1 Service launches
16.1.8.3.2 Deals
16.1.9 IQVIA INC.
16.1.9.1 Business overview
16.1.9.2 Services offered
16.1.9.3 Recent developments
16.1.9.3.1 Deals
16.1.9.3.2 Expansions
16.1.10 CHARLES RIVER LABORATORIES
16.1.10.1 Business overview
16.1.10.2 Services offered
16.1.10.3 Recent developments
16.1.10.3.1 Deals
16.1.11 BIO-RAD LABORATORIES, INC.
16.1.11.1 Business overview
16.1.11.2 Products/Services offered
16.1.11.3 Recent developments
16.1.11.3.1 Product launches
16.1.11.3.2 Deals
16.1.12 EUROFINS SCIENTIFIC
16.1.12.1 Business overview
16.1.12.2 Products/Services offered
16.1.12.3 Recent developments
16.1.12.3.1 Product launches
16.1.12.3.2 Deals
16.1.13 PACBIO
16.1.13.1 Business overview
16.1.13.2 Products/Services offered
16.1.13.3 Recent developments
16.1.13.3.1 Product & service launches
16.1.13.3.2 Deals
16.1.13.3.3 Expansions
16.1.13.3.4 Other developments
16.1.14 OXFORD NANOPORE TECHNOLOGIES PLC.
16.1.14.1 Business overview
16.1.14.2 Products/Services offered
16.1.14.3 Recent developments
16.1.14.3.1 Product & service launches
16.1.14.3.2 Deals
16.1.15 TAKARA BIO INC.
16.1.15.1 Business overview
16.1.15.2 Products/Services offered
16.1.15.3 Recent developments
16.1.15.3.1 Product & service launches
16.1.15.3.2 Deals
16.1.16 BGI GROUP
16.1.16.1 Business overview
16.1.16.2 Products/Services offered
16.1.16.3 Recent developments
16.1.16.3.1 Product & service launches
16.1.16.3.2 Deals
16.1.16.3.3 Other developments
16.1.17 EPPENDORF SE
16.1.17.1 Business overview
16.1.17.2 Products/Services offered
16.1.17.3 Recent developments
16.1.17.3.1 Product & service launches
16.1.18 MERCK KGAA
16.1.18.1 Business overview
16.1.18.2 Products/Services offered
16.1.18.3 Recent developments
16.1.18.3.1 Expansions
16.1.19 BD
16.1.19.1 Business overview
16.1.19.2 Products/Services offered
16.1.19.3 Recent developments
16.1.19.3.1 Product & service launches
16.1.19.3.2 Deals
16.1.20 ABBOTT
16.1.20.1 Business overview
16.1.20.2 Products/Services offered
16.1.20.3 Recent developments
16.1.20.3.1 Product & service launches
16.1.21 10X GENOMICS
16.1.21.1 Business overview
16.1.21.2 Products/Services offered
16.1.21.3 Recent developments
16.1.21.3.1 Product launches
16.1.22 NEW ENGLAND BIOLABS
16.1.22.1 Business overview
16.1.22.2 Products/Services offered
16.1.22.3 Recent developments
16.1.22.3.1 Product & service launches
16.1.22.3.2 Deals
16.1.23 PROMEGA CORPORATION
16.1.23.1 Business overview
16.1.23.2 Products/Services offered
16.1.23.3 Recent developments
16.1.23.3.1 Product & service launches
16.1.23.3.2 Other developments
16.2 OTHER PLAYERS
16.2.1 CREATIVE BIOGENE
16.2.2 NOVOGENE CO., LTD.
16.2.3 HELIX, INC.
16.2.4 PHALANX BIOTECH GROUP
16.2.5 POLARIS GENOMICS

17 APPENDIX
17.1 DISCUSSION GUIDE
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
17.3 CUSTOMIZATION OPTIONS
17.4 RELATED REPORTS
17.5 AUTHOR DETAILS